No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CVAC CureVac
- 3.270
- +0.160+5.14%
Close Jul 11 16:00 ET
- 3.150
- -0.120-3.67%
Post 19:58 ET
733.48MMarket Cap-2466P/E (TTM)
3.300High3.110Low1.19MVolume3.270Open3.110Pre Close3.85MTurnover0.97%Turnover RatioLossP/E (Static)224.31MShares10.19052wk High1.51P/B400.61MFloat Cap2.21552wk Low--Dividend TTM122.51MShs Float151.800Historical High--Div YieldTTM6.11%Amplitude2.215Historical Low3.229Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | CureVac NV: UK Trial on Validity of Intellectual Property Rights Ep 3 708 668 B1 and Ep 4 023 755 B1 Began July 10; Judgement Expected Later in 2024
Express News | CureVac NV - New Trial Date for U.S. Patent Litigation Set for March 3, 2025, Following Settlement With Acuitas Therapeutics
CureVac: A Buy Rating Amidst Intellectual Property Litigation and Strong Valuation Metrics
CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology)
Express News | CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
Agomab Bolsters Executive Team With Appointment of Pierre Kemula as Chief Financial Officer
Comments
$CureVac(CVAC.US$ CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany
Benzinga· 1 min ago
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent liti...
Benzinga· 1 min ago
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent liti...
1
$CureVac(CVAC.US$ Good news and people still sell wtf lol
1
$CureVac(CVAC.US$ It's going up up up today the volume already almost as much as it was pre-market yesterday.After Novavax deal they rocketed!
$CureVac(CVAC.US$ GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Bln
4
10
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg